Question-and-Answer Session
Operator
(Operator Instructions) Our first question will come from the line of Ted Neville, private investor. Please proceed.
Ted Neville – Private Investor
Hello, everyone. Dan, you mentioned that we had completed animal studies and that we are evaluating the next steps with BioCryst. I assume the animal studies were encouraging. Is it logical to think that the next steps will be human studies? And if so, when would they start and how long would it take?
Daniel Wilds
Good morning, Ted. You know, we've been working on this collaboration with BioCryst now for quite some time. And, yes, we generally are encouraged by the results we've seen today. The next steps are under consideration with BioCryst, and I really can't divulge more than that at this point in time until they get back to us with feedback as to what they are going to agree to do and not to do. But, again, I'm very optimistic that this program has a very bright future.
Ted Neville – Private Investor
Okay, great. Have another question if that's okay?
Daniel Wilds
Sure.
Ted Neville – Private Investor
Back in April 2003 BD, before Dan, we announced that SCOLR was preparing to ship glucosamine to us first - first to market European customer. The customer was Springfield Nutraceuticals located in the Netherlands. Whatever happened with this, and are we still pursuing the European market concerning Nutraceuticals?
Daniel Wilds
Yes, let me do a couple of things. One, since I wasn't here during that time frame, that program actually had ended before I arrived. So we'll let Steve address that. And then we can address a little bit more what our thinking is for the international market. Steve.
Ted Neville – Private Investor
Okay.
Stephen Turner
Yeah. Back in 2003 we had actually begun shipping very small quantities to Springfield Nutraceuticals in the Netherlands. And they were hoping to, basically, sell the product both in the Netherlands as well as maybe try to enter into the European markets. It was very low-volume, and never really had an opportunity to grow or expand. I do not believe that we ever got into a second shipment with that particular group. And the primary customer, I think, really from that point forward continues to be Wal-Mart through the Perrigo relationship.
Daniel Wilds
Relative to what our thinking continues to be in the international area for the dietary supplements, we've talked about this in a number of public presentations, Ted, which really relates to the fact that we wanted to get a portfolio of five or six products before we really try to pursue a partnership or liaison in Europe, to be able to market products there that really contain, in the nutraceutical area, our CDT technology.
- To read the full transcript on Seeking Alpha, click here »
